MARKET

VSTM

VSTM

Verastem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.450
0.000
0.00%
After Hours: 1.430 -0.02 -1.38% 19:59 07/10 EDT
OPEN
1.440
PREV CLOSE
1.450
HIGH
1.520
LOW
1.435
VOLUME
4.54M
TURNOVER
--
52 WEEK HIGH
4.670
52 WEEK LOW
0.8300
MARKET CAP
235.67M
P/E (TTM)
-0.7896
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VSTM stock price target is 3.833 with a high estimate of 5.00 and a low estimate of 3.000.

EPS

VSTM News

More
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 4d ago
Hedge Funds Never Loved Verastem Inc (VSTM) More
In this article we will take a look at whether hedge funds think Verastem Inc (NASDAQ:VSTM) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on I
Insider Monkey · 06/24 03:07
Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma
Business Wire · 06/22 21:05
Verastem Oncology Highlights Presentation Of Preclinical Data Supporting Combo Of VS-6766, Defactinib In Metastatic Uveal Melanoma
Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from a study
Benzinga · 06/22 20:07
Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference
Business Wire · 05/28 12:00
Billionaire Steven Cohen Bets Big on These 3 Stocks
TipRanks · 05/19 14:47
Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?
Zacks · 05/18 16:20
3 Biotech Stocks Under $4 With at Least 50% Upside Potential
TipRanks · 05/14 14:31

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About VSTM

Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include COPIKTRA (Duvelisib) and defactinib and the programs include CH5126766 also referred to as VS-6766. Defactinib, is a targeted inhibitor of Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer.
More

Webull offers kinds of Verastem Inc stock information, including NASDAQ:VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.